United Therapeutics Corp (UTHR): Martine A Rothblatt , Chairman & Co-CEO of United Therapeutics Corp sold 5,546 shares on May 5, 2016. The Insider selling transaction was reported by the company on May 6, 2016 to the Securities and Exchange Commission. The shares were sold at $107.94 per share for a total value of $597,780.62 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 29, 2016, Martine A Rothblatt (Chairman & Co-CEO) sold 5,547 shares at $106.40 per share price.On Apr 4, 2016, Raymond Dwek (director) sold 3,000 shares at $110.79 per share price.Also, On Mar 3, 2016, Tommy G Thompson (director) sold 3,000 shares at $126.54 per share price.On Nov 4, 2015, Richard Giltner (director) sold 7,500 shares at $153.22 per share price.
Shares of United Therapeutics Corporation (UTHR) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -2.35 points or -2.13% at $108.2 with 7,90,136 shares getting traded. Post opening the session at $110.36, the shares hit an intraday low of $107.77 and an intraday high of $111.23 and the price vacillated in this range throughout the day. The company has a market cap of $4,828 M and the number of outstanding shares has been calculated to be 4,46,21,988 shares. The 52-week high of United Therapeutics Corporation is $190.13 and the 52-week low is $102.5.
Company has been under the radar of several Street Analysts.United Therapeutics Corporation is Downgraded by Ladenburg Thalmann to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 29, 2016.United Therapeutics Corporation is Reiterated by RBC Capital Mkts to Sector Perform while Lowering the Price Target of the company shares to $ 122 from a previous price target of $150 . The Rating was issued on Apr 11, 2016.United Therapeutics Corporation is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 229 from a previous price target of $238 . The Rating was issued on Mar 28, 2016.United Therapeutics Corporation is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 238 from a previous price target of $244 . The Rating was issued on Mar 2, 2016.United Therapeutics Corporation is Upgraded by Standpoint Research to Buy and the brokerage firm has set the Price Target at $148. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Feb 10, 2016.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.